Form 8-K - Current report:
SEC Accession No. 0001140361-24-037388
Filing Date
2024-08-15
Accepted
2024-08-15 06:05:51
Documents
112
Period of Report
2024-08-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20030749x9_8k.htm   iXBRL 8-K 208579
2 EXHIBIT 99.1 ny20030749x9_ex99-1.htm   iXBRL EX-99.1 1371528
  Complete submission text file 0001140361-24-037388.txt   11339074

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20240815.xsd EX-101.SCH 109542
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE mcrb-20240815_cal.xml EX-101.CAL 91275
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mcrb-20240815_def.xml EX-101.DEF 511137
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20240815_lab.xml EX-101.LAB 1423459
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20240815_pre.xml EX-101.PRE 758578
115 EXTRACTED XBRL INSTANCE DOCUMENT ny20030749x9_8k_htm.xml XML 1730524
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 241210491
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)